Drug Monograph Updates
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of June. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…
Drug Monograph
Baricitinib 1mg, 2mg, 4mg; tabs.
Select the therapeutic use below to view the corresponding drug monograph
Visit the related Resource Center for drug monographs, news, CME and other clinical tools for this drugs’ particular therapeutic area.
News
The approval was based on data from the phase 2/3 BRAVE-AA1 and phase 3 BRAVE-AA2 trials, which included adults with severe alopecia areata.
News
The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.
Drug Monograph
Abrocitinib 50mg, 100mg, 200mg; tabs.
Select the therapeutic use below to view the corresponding drug monograph
Visit the related Resource Center for drug monographs, news, CME and other clinical tools for this drugs’ particular therapeutic area.
New Drug Products
Review the January 2022 notable drug approvals.
Drugs in the Pipeline
Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.
